No Clinically Significant Interaction Between Vyvanse and Bactrim
There is no documented clinically significant drug interaction between lisdexamfetamine (Vyvanse) and sulfamethoxazole-trimethoprim (Bactrim), and these medications can be safely co-administered in most patients.
Key Considerations
Direct Drug Interaction Evidence
The available evidence does not identify any direct pharmacokinetic or pharmacodynamic interaction between these two medications:
- Lisdexamfetamine is a prodrug that is hydrolyzed in the blood to d-amphetamine, which then acts on dopamine and noradrenaline transporters 1
- Bactrim (TMP-SMX) primarily inhibits CYP2C8 (trimethoprim) and CYP2C9 (sulfamethoxazole) 2
- Amphetamines are not significantly metabolized through these cytochrome P450 pathways—approximately 80% of methylphenidate metabolism is extrahepatic 3, and lisdexamfetamine's conversion to d-amphetamine occurs via hydrolysis in red blood cells, not hepatic metabolism
Cardiovascular Monitoring Remains Important
While no interaction exists, both medications have cardiovascular considerations that require standard monitoring:
For Lisdexamfetamine:
- Monitor heart rate and blood pressure regularly 4
- Contraindicated in uncontrolled hypertension, hyperthyroidism, and with MAOIs 4
- Risk of peripheral vasculopathy including Raynaud's phenomenon 5
For Bactrim:
- Sulfamethoxazole can cause QT prolongation and torsades de pointes in rare cases, particularly in patients with genetic polymorphisms affecting potassium channels 6
- This risk is independent of lisdexamfetamine use
Practical Clinical Approach
When co-prescribing these medications:
Baseline assessment: Check blood pressure and heart rate before initiating lisdexamfetamine (standard practice regardless of Bactrim use)
Monitor cardiovascular parameters: Continue routine monitoring as you would for any patient on stimulant therapy—no additional monitoring is needed specifically for the combination
Watch for additive cardiovascular effects: While not a true drug interaction, be aware that if a patient develops tachycardia or hypertension, either medication could be contributing
No dose adjustments needed: Neither medication requires dose modification when used together
Common Pitfalls to Avoid
- Do not confuse with MAOI interactions: Lisdexamfetamine is contraindicated with MAOIs (risk of hypertensive crisis) 4, but Bactrim is not an MAOI
- Do not confuse with warfarin interactions: Bactrim has significant interactions with warfarin 7, 8, 9, but this is irrelevant to lisdexamfetamine
- Do not confuse with serotonergic interactions: While lisdexamfetamine carries a warning about serotonin syndrome 5, this occurs with serotonergic agents (SSRIs, MAOIs, etc.), not with Bactrim
Special Populations
Renal impairment: Both medications require dose adjustment in renal dysfunction, but these adjustments are independent of each other 7, 5